Autolus Therapeutics vs Coherus Oncology
AUTL and CHRS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AUTL and CHRS compare
Autolus Therapeutics is the larger company, worth 3.9 times as much as Coherus Oncology ($290M against $73.9M).
Autolus Therapeutics grew revenue faster over the last twelve months (292% versus 61.0% for Coherus Oncology).
Autolus Therapeutics keeps more of each dollar of sales as profit, with a net margin of −239% compared with −259% at Coherus Oncology.
Coherus Oncology scores higher on the StockData Score (7 against 5 for Autolus Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AUTL | CHRS |
|---|---|---|
| Size and price | ||
| Market cap | $290M | $73.9M |
| Share price | $1.09 | $0.478 |
| Change, 1 year | −20.4% | −59.8% |
| Change, 5 years | −82.6% | −97.4% |
| Beta (5Y) | 3.47 | 0.88 |
| Employees | 754 | 147 |
| StockData Score | ||
| Total score | 5 | 7 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.5× | 1.5× (better) |
| P/B | 3.9× | 1.2× (better) |
| FCF yield | −80.2% | – |
| Fair value | $1.36 | $1.16 |
| Margin of safety | 19.8% | 58.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 292% (better) | 61.0% |
| Revenue growth, 5Y average | – | −38.4% |
| Net income growth (TTM) | – | −174% |
| EPS growth, 5Y average | – | −2.5% |
| Profitability | ||
| Gross margin | 15.7% | 68.9% (better) |
| Operating margin | −211% (better) | −312% |
| Net margin | −239% (better) | −259% |
| FCF margin | −198% | – |
| Return on equity | −133% (better) | −146% |
| Financial health | ||
| Interest coverage | −5.9× (better) | −17.5× |
| Current ratio | 4.89 (better) | 1.77 |
| Altman Z-score | −4.60 (better) | −12.33 |
| Piotroski F-score | 2 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 49.7% | 45.5% |
| Held by insiders | 24.6% | 1.3% |
| Insider net buying, 12 months | −$15.7K | – |
| Short interest, % of float | – | 8.3% |
Go deeper
- AUTL stock overview
- AUTL income statement
- AUTL valuation and score
- CHRS stock overview
- CHRS income statement
- CHRS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.